Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive and universally fatal neurodegenerative disorder. In Europe, Australia and Canada, riluzole is the only approved therapeutic agent for the treatment of ALS, while in the USA, riluzole and edaravone have been approved by...

Descripción completa

Detalles Bibliográficos
Autores principales: Vucic, Steve, Kiernan, Matthew C, Menon, Parvathi, Huynh, William, Rynders, Austin, Ho, Karen S, Glanzman, Robert, Hotchkin, Michael T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802642/
https://www.ncbi.nlm.nih.gov/pubmed/33431491
http://dx.doi.org/10.1136/bmjopen-2020-041479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802642/
https://www.ncbi.nlm.nih.gov/pubmed/33431491
http://dx.doi.org/10.1136/bmjopen-2020-041479

Ejemplares similares